文献速递肾癌与肾肿瘤

家族性肾癌:新综合征的意义与分子见解

Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.
PubMed 文献 · Eur Urol · 2019-07-18

本文系统综述了遗传性肾细胞癌(RCC)综合征的近期临床前与临床文献,涵盖VHL、MET、FH、TSC1/TSC2、FLCN、SDHA/B/C/D、BAP1、CDC73和MITF等基因胚系致病性变异相关综合征,指出SDH、BAP1和MITF相关RCC临床表现谱尚待明确,FH及可能BAP1相关RCC侵袭性更强,利用特定遗传通路的全身治疗是有前景的策略。

要点

  • 遗传性RCC约占所有RCC的5%。
  • 已描述多个常染色体显性遗传RCC综合征,涉及VHL、MET、FH、TSC1/TSC2、FLCN、SDHA/B/C/D、BAP1、CDC73和MITF等基因。
  • FH及可能BAP1相关RCC与更具侵袭性的疾病相关;利用特定遗传通路的全身治疗是有前景的策略。

核心结论

  • 已明确描述多个遗传性RCC综合征及近期发现的新综合征,后者完整临床谱尚待确定;在精准医学新时代,识别这些综合征可能在管理和全身治疗选择中发挥重要作用。

研究设计与样本

  • 2018年11月使用PubMed和OMIM数据库进行系统文献综述,重点关注肾癌、遗传学与基因组学、临床标准和管理。

主要发现

  • 已描述多个常染色体显性遗传RCC综合征,包括与VHL、MET、FH、TSC1/TSC2、FLCN、SDHA/B/C/D、BAP1、CDC73和MITF胚系致病性变异相关的综合征。
  • SDH、BAP1和MITF的临床谱仍在定义中,尽管这些似乎与较低的RCC发生率相关。
  • FH和可能BAP1相关RCC与更具侵袭性的疾病相关。
  • 临床前和临床研究显示,利用特定遗传通路的全身治疗是一种有前景的策略。

关键数值与推荐

  • 遗传性病例约占所有RCC病例的5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • SDH、BAP1和MITF的完整临床谱尚待定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hereditary cases account for about 5% of all cases of renal cell carcinoma (RCC). With advances in next-generation sequencing, several new hereditary syndromes have been described in the last few years. OBJECTIVE: To review and summarise the recent preclinical and clinical literature in hereditary renal cancer. EVIDENCE ACQUISITION: A systematic review of the literature was performed in November 2018 using PubMed and OMIM databases, with an emphasis on kidney cancer, genetics and genomics, clinical criteria, and management. EVIDENCE SYNTHESIS: Several autosomal dominant hereditary RCC syndromes have been described, including those related to germline pathogenic variants in VHL, MET, FH, TSC1/TSC2, FLCN, SDHA/B/C/D, BAP1, CDC73, and MITF. Clinical spectrum of SDH, BAP1, and MITF is still being defined, although these appear to be associated with a lower incidence of RCC. FH and likely BAP1 RCC are associated with more aggressive disease. Preclinical and clinical studies show that using systemic therapy that exploits specific genetic pathways is a promising strategy. CONCLUSIONS: There are several well-described hereditary RCC syndromes, as well as recently identified ones, for which the full clinical spectrum is yet to be defined. In the new era of precision medicine, identification of these syndromes may play an important role in management and systemic treatment selection. PATIENT SUMMARY: This review covers updates in the diagnosis and management of familial kidney cancer syndromes. We describe updates in testing and management of the most common syndromes such as von Hippel-Lindau, and hereditary leiomyomatosis and renal cell carcinoma. We also provide insights into recently described familial kidney cancer syndromes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Carlo MI, Hakimi AA, Stewart GD, et al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. Eur Urol. 2019. PMID: 31326218. doi:10.1016/j.eururo.2019.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。